Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Conditions:   Non-Small Cell Lung Cancer;   ALK Gene Rearrangement Positive Intervention:   Drug: Ensartinib Sponsor:   Xcovery Holding Company, LLC Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials